Sharma, Ashish http://orcid.org/0000-0002-8550-9791
Kumar, Nilesh http://orcid.org/0000-0002-7439-2081
Parachuri, Nikulaa
Regillo, Carl D.
Bandello, Francesco http://orcid.org/0000-0003-3238-9682
Kuppermann, Baruch D.
Article History
Received: 6 December 2021
Revised: 3 February 2022
Accepted: 10 February 2022
First Online: 21 February 2022
Competing interests
: AS: consultant for Novartis, Allergan, Bayer and Intas. CDR: consultant for Allergan, Chengdu Kanghong, Genentech/Roche, Novartis, Kodiak, Notal, Merck, Shire-Takeda, Adverum, Graybug, and Eyepoint and receives research support from Allergan, Chengdu Kanghong, Genentech/Roche, Novartis, Kodiak, Iveric, and Adverum. FB: consultant for Allergan, Bayer, Boehringer-Ingelheim, FidiaSooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. BDK: clinical research: Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, ThromboGenics; consultant for Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, Theravance Biopharma. NK and NP: None.